慢性丙型肝炎患者获得快速病毒学应答的预测因素分析

张丹丹; 叶佩燕; 黄玉仙; 徐国光; 张毅; 李新艳; 陈良

doi:10.3969/j.issn.1001-5256.2014.12.019

慢性丙型肝炎患者获得快速病毒学应答的预测因素分析

DOI: 10.3969/j.issn.1001-5256.2014.12.019

上海市公共卫生临床中心肝炎一科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2510
- HTML全文浏览量: 20
- PDF下载量: 575
- 被引次数: 0
出版历程
- 收稿日期: 2014-06-04
- 出版日期: 2014-12-20

Analysis of predictive factors for rapid virologic response in treating patients with chronic hepatitis C

First Department of Hepatitis, Shanghai Public Health Clinical Center

摘要

摘要: 目的探讨联合应用聚乙二醇干扰素（PEG-IFN）和利巴韦林治疗的慢性丙型肝炎（CHC）患者获得快速病毒学应答（RVR）的预测因素。方法采用回顾性队列研究方法,对上海市公共卫生临床中心肝病科2010-2012年收治的127例接受PEGIFN联合利巴韦林治疗的CHC患者进行分析,根据抗病毒治疗4周后是否获得RVR,将研究对象分为RVR组和无快速病毒学应答（NRVR）组,比较两组人口学特征及治疗前的临床特征,分析影响CHC患者获得RVR的可能因素。计数资料采用卡方检验,影响因素的分析采用两个独立样本的非参数检验即Mann-Whitney U检验,独立预测因素采用单因素及多因素Logistic回归分析,预测因素中的连续变量作ROC曲线分析。结果 127例患者中,男86例,女41例,其中明确诊断为肝硬化的11例。127例中100例（78.74%）获得RVR,NRVR患者27例（21.26%）。非参数分析显示,对于患者年龄、感染时间、基线ALT水平、基线HA水平、是否合并高血压病、干扰素种类、感染途径、病毒基因型这些因素,RVR组和NRVR组差异均有统计学意义（P值均<0.05）。Logis...
- 肝炎,丙型,慢性 /
- 病毒学应答 /
- 因素分析,统计学
Abstract: Objective To analyze the predictive factors for rapid virologic response (RVR) in patients with chronic hepatitis C (CHC) who received combination therapy with pegylated interferon (PEG-IFN) and ribavirin. Methods A total of 127 CHC patients who were admitted to our department from 2010 to 2012 and received PEG-IFN combined with ribavirin were enrolled in this retrospective cohort study. The patients were divided into RVR group and non-RVR (NRVR) group according to their virologic responses after 4 weeks of antiviral therapy.Demographic characteristics and the clinical features prior to treatment were compared between the two groups, and the potential factors that contributed to the acquisition of RVR were analyzed. Comparison of categorical data between groups was made by chi-square test, predictive factors were analyzed by nonparametric test for two independent samples (Mann-Whitney U test) , independent predictive factors were tested by univariate and multivariate logistic regression analyses, and the continuous variables of predictive factors were analyzed using receiver operating characteristic curves. Results Of the 127 CHC patients, 86 were males and 41 females. There were 11 confirmed cases of liver cirrhosis. There were 100 patients (78. 74%) who achieved an RVR, and 27 (21. 26%) with NRVR. Nonparametric analysis showed that eight factors, which were age, time of infection, level of pre-treatment alanine aminotransferase, level of pre-treatment hyaluronic acid, development of hypertension, type of interferon, pathway of infection, and hepatitis C virus (HCV) genotype, were significantly different between the RVR and NRVR groups (P < 0. 05) . The logistic regression analysis identified the following factors as independent predictive factors for RVR: non-genotype 1 (OR: 0. 203, 95% CI: 0. 051-0. 802, P < 0. 05) , time of infection (OR: 0. 925, 95% CI: 0. 868-0. 987, P < 0. 05) , and absence of hypertension (OR: 0. 129, 95% CI: 0. 032-0. 521, P < 0. 05) . Conclusion Patients with shorter history of HCV infection, absence of complicated hypertension, and non-genotype 1 HCV infection have an increased likelihood of achieving an RVR.
- hepatitis C, chronic /
- virologic response /
- factor analysis, statistical

HTML全文

参考文献(14)

[1]van der MEER AJ, VELDT BJ, FELD JJ, et al.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis sustained virological response and all-cause mortality[J].JAMA, 2012, 308 (24) :2584-2593.

[2]YU JW, WANG GQ, SUN LJ, et al.Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin[J].J Gastroenterol Hepatol, 2007, 22 (6) :832-836.

[3]HADZIYANNIS SJ, SETTE H JR, MORGAN TR, et al.Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.

[4]FERENCI P, FRIED MW, SHIFFMAN ML, et al.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) /ribavirin[J].J Hepatol, 2005, 43 (3) :425-433.

[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology, Chinese Medical Association.Guidelines for prevention and treatment of hepatitis C[J].J Clin Hepatol, 2004, 20 (4) :197-203. (in Chinese) 中华医学会肝病学分会, 中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.

[6]MANNS MP, MCHUTCHISON JG, GORDON SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial[J].Lancet, 2001, 358 (9286) :958-965.

[7]CAMMC, PETTA S, ENEA M, et al.Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C[J].Hepatology, 2012, 56 (3) :850-860.

[8]GILL U, AZIZ H, GILL ML.Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan[J].Int J Infect Dis, 2013, 17 (11) :e1017-e1021.

[9]CHENG ML, WANG J, ZENG AP, et al.The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response[J].Chin J Intern Med, 2012, 51 (10) :751-754. (in Chinese) 程茂良, 王珏, 曾爱平, 等.慢性丙型肝炎个体化治疗及其病毒学应答效果影响因素分析研究[J].中华内科杂志, 2012, 51 (10) :751-754.

[10]El RAZIKY M, FATHALAH WF, El AKEL WA, et al.The effect of peginterferon alpha-2a vs.peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients:a single centre egyptian study[J].Hepat Mon, 2013, 13 (5) :e10069.

[11]SINGAL AG, DHARIA TD, MALET PF, et al.Long-term benefit of hepatitis C therapy in a safety net hospital system:a cross-sectional study with median 5-year follow-up[J].BMJ Open, 2013, 3 (9) :e003231.

[12]XU Z, ZHANG XH, ZHAO ZX, et al.Analysis for the predictors of rapid virological response in therapy of patients with chronic hepatitis C of high viral loads[J/CD].Chin J Clinicians:Electronic Edition, 2011, 5 (18) :5327-5330. (in Chinese) 许镇, 张晓红, 赵志新, 等.高病毒载量慢性丙型肝炎快速病毒学应答的预测因素分析[J/CD].中华临床医师杂志:电子版, 2011, 5 (18) :5327-5330.

[13]DOU XG.The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients[J].Chin J Hepatol, 2013, 21 (6) :406-407. (in Chinese) 窦晓光.影响丙型肝炎初治患者标准化治疗疗效的相关因素及对策[J].中华肝脏病杂志, 2013, 21 (6) :406-407.

[14]MARIA P, SOFIA M, RAFFAELE M, et al.Chronic HCV infection affects cardiac mass in normotensives[J].J Hepatol, 2014.

施引文献

资源附件(0)

访问统计